Key Highlights
- CLGN Penny Stock fell 6.20% pre-market to $0.32, extending a 7.86% decline in the prior session.
- The Board approved a one-for-ten reverse share split effective when trading opens September 4, 2026.
- The move is intended to help the company regain compliance with Nasdaq's minimum bid price requirement.
- Shareholders approved the split at an Extraordinary General Meeting held August 18, 2026.
- The company's 52-week range spans $0.26 to $3.18, with a market cap near $4.45 million.
Reverse Split Set to Take Effect This Week
CollPlant Biotechnologies (NASDAQ:CLGN) penny stock declined in pre-market trading after the company confirmed that its previously approved one-for-ten reverse share split will take effect when the Nasdaq Capital Market opens on September 4, 2026. Every ten existing shares will convert into one share, with fractional shares rounded to the nearest whole share and no cash paid out for fractions.
CollPlant is an Israel-based regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs, tissue repair, and medical aesthetics, built around its proprietary plant-based recombinant human collagen technology.
Move Aimed at Preserving Nasdaq Listing
The company said the split is part of its strategic plan to regain compliance with Nasdaq's minimum bid price requirement for continued listing. A corresponding adjustment will also be made to the exercise price and share count of all outstanding warrants and options. Shareholders holding shares through a bank or broker do not need to take any action, while those holding physical certificates will receive exchange instructions from the company's transfer agent.
The stock's fall pre-market reflects a common pattern around reverse split announcements, where existing shareholders often price in dilution concerns or view the mechanical share consolidation as a signal of financial pressure, even though the split itself does not change the company's underlying market value.
Pending Acquisition Adds Another Layer to the Story
CollPlant has also disclosed a definitive agreement to acquire an Israeli deep-tech company working on laser-based computing architecture, a transaction still subject to closing conditions. The company's small market Capitalization of roughly $4.45 million reflects its penny stock status and the significant losses it has reported to date, alongside its stated need for additional capital.
Compliance Timeline Now the Key Catalyst to Watch
With the reverse split taking effect this week, investors will watch whether the post-split share price stabilizes above Nasdaq's minimum bid threshold. The pending acquisition remains a separate, unresolved catalyst that could shape the company's strategic direction independent of the listing compliance issue.
_11_16_2026_14_38_45_453029.jpg)





Please wait processing your request...